On February 3, 2021, the results of the fourth batch of centralized procurement of national drugs were released. Mothapryl citrate tablets (trademark name: Ambili®), independently developed by Fujian Haixi New Drug Creation Co., Ltd., won the bid in the second place, with ten supply provinces (regions) including Beijing, Tianjin, Inner Mongolia, Jilin
Haixi New Drug Ambili® was approved for listing in June 2020. As a consistent evaluation, it is the first moxabride tablet approved according to the new four categories of chemical drugs in China.
Ambili® is a new generation of gastrodynamic drugs, which has the characteristics of high safety (low adverse reactions, no cardiac toxicity), wide range of functions (full gastrointestinal mot motides), and a wide range of indications. Clinically, it can be used for functional dyspepsia, esophageal reflux, gastric paralysis, constipation, capsule microscopy, etc. As the first drug listed on the company, the winning bid for the centralized procurement of drugs will lay a solid foundation for the company's sustainable development.
As the first R&D enterprise in Fujian Province to obtain the Pharmaceutical Production License as a Listing License Holder (MAH), the company's development is not only due to the country's continuous and in-depth pharmaceutical reform, but also from the strong support and help of leaders of Fujian Provincial Drug Administration and other government departments at all levels, as well as friends from all walks of life. In the future, the company will continue to strengthen research and development, optimize the production process, and continue to reduce costs under the premise of good quality control, so that people can use more assured drugs of high quality, good price and good performance.
